Sanofi waves the white flag on Reg­u­lus' mi­croR­NA pro­gram tar­get­ing rare kid­ney dis­ease

Sanofi is scrap­ping a drug from a long­time part­ner.

The Big Phar­ma tells End­points News it has halt­ed de­vel­op­ment of lademirsen, dis­cov­ered by Reg­u­lus Ther­a­peu­tics, af­ter the pro­gram failed a Phase II in­ter­im analy­sis. Sanofi added that the move was not due to safe­ty con­cerns. Lademirsen is de­signed to slow kid­ney func­tion de­cline in pa­tients with Al­port syn­drome.

“While this tri­al did not pro­vide the re­sults we had an­tic­i­pat­ed, our re­search has added val­ue to the sci­en­tif­ic un­der­stand­ing of Al­port Syn­drome, and we re­main com­mit­ted to ad­vanc­ing new ther­a­pies for rare kid­ney dis­eases,” a Sanofi spokesper­son told End­points.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER